Neovasc stock (NVCN) is surging: what’s next?
Just yesterday Neovasc resolved potential legal claims that could be brought against the company with the University of Pennsylvania (a.k.a. Penn). The firm has signed a collaboration and licensing agreement with Penn's Gorman Cardiovascular Research Group. Based on the agreement, for a period of time over the next four years Neovasc will pay a fee to Penn. The company will also pay a royalty on Tiara, its cornerstone product, to Penn. This agreement does not impact either Penn's or Neovasc's patent rights, and it also contains buyout clauses which allow a potential acquirer to buy out the royalty obligations.
This is significant news for the company that received a delisting notification from Nasdaq. Regarding delisting, Neovasc will request a hearing before the Nasdaq Hearings Panel as the next step, seeking an additional 180-day extension for compliance with the $1 minimum bid price requirement.
finstead.com/bite/Neovasc-NVCN-stock-forecast-prediction-august-4-2018
This is significant news for the company that received a delisting notification from Nasdaq. Regarding delisting, Neovasc will request a hearing before the Nasdaq Hearings Panel as the next step, seeking an additional 180-day extension for compliance with the $1 minimum bid price requirement.
finstead.com/bite/Neovasc-NVCN-stock-forecast-prediction-august-4-2018
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.